#1 Clinical Trials Search in Europe

Irinotecan

Irinotecan, also known as CPT-11 or Camptosar, is a chemotherapy drug being studied in various clinical trials for its effectiveness in treating different types of cancer. These trials aim to determine optimal dosing, evaluate its efficacy when combined with other treatments, and assess its potential in addressing advanced stages of cancer, particularly colorectal cancer and other solid tumors.

Table of Contents

What is Irinotecan?

Irinotecan is a chemotherapy drug used to treat various types of cancer. It is also known by several other names, including CPT-11, Camptosar, and Campto[1]. Irinotecan belongs to a class of drugs called topoisomerase I inhibitors, which work by interfering with the DNA in cancer cells, preventing them from dividing and growing[2].

What Conditions Does Irinotecan Treat?

Irinotecan is primarily used to treat the following conditions:

  • Metastatic Colorectal Cancer: This is cancer that has spread from the colon or rectum to other parts of the body. Irinotecan is commonly used as a treatment for this condition[1][3].
  • Advanced Solid Tumors: Irinotecan may be used in clinical trials to treat various types of advanced solid tumors[2].
  • Non-small Cell Lung Cancer: Some studies have explored the use of irinotecan in treating certain types of lung cancer[4].
  • Glioblastoma: This is an aggressive type of brain cancer. Irinotecan has been studied in combination with other drugs for treating recurrent glioblastoma[5].

How is Irinotecan Administered?

Irinotecan is typically administered intravenously (through a vein) in a hospital or clinic setting. The dosage and frequency can vary depending on the specific treatment plan, but some common administration methods include:

  • 90-minute intravenous infusion every two weeks[1]
  • 60-minute intravenous infusion every two weeks[6]
  • 30-minute intravenous infusion weekly for several weeks[5]

The exact dosage is usually calculated based on the patient’s body surface area (measured in mg/m²) and may be adjusted depending on how well the patient tolerates the treatment.

Irinotecan Combination Therapies

Irinotecan is often used in combination with other drugs to enhance its effectiveness. Some common combination therapies include:

  • FOLFIRI: This regimen combines irinotecan with fluorouracil (5-FU) and leucovorin. It is commonly used in treating metastatic colorectal cancer[7].
  • FOLFOXIRI: This intensive regimen combines irinotecan with oxaliplatin, fluorouracil, and leucovorin. It may be used in combination with targeted therapies like bevacizumab for metastatic colorectal cancer[8].
  • Irinotecan + Cetuximab: This combination has been studied for treating metastatic colorectal cancer, especially in patients whose cancer has specific genetic characteristics (KRAS and NRAS wild-type)[3].
  • Irinotecan + Capecitabine + Bevacizumab: This three-drug combination has been studied for metastatic colorectal cancer[9].

Potential Side Effects

Like all chemotherapy drugs, irinotecan can cause side effects. Some potential side effects include:

  • Diarrhea: This is a common side effect that can be severe in some cases[5].
  • Nausea and vomiting
  • Decreased blood cell counts: This can lead to an increased risk of infection, anemia, or bleeding[5].
  • Fatigue
  • Hair loss

Your healthcare team will monitor you closely for these and other side effects and may adjust your treatment if necessary.

Ongoing Research and Clinical Trials

Researchers continue to study irinotecan to find new ways to use it effectively and to understand how it interacts with other drugs. Some areas of ongoing research include:

  • Using irinotecan in combination with newer targeted therapies[1][3]
  • Exploring different dosing schedules to improve efficacy and reduce side effects[9]
  • Investigating the use of irinotecan in treating other types of cancer[4]
  • Studying how genetic factors might influence a patient’s response to irinotecan[4]

If you’re interested in participating in a clinical trial involving irinotecan, discuss this option with your oncologist. They can help you understand if any current trials might be suitable for your specific situation.

Aspect Details
Cancer Types Studied Colorectal cancer, malignant glioma, cervical cancer, sarcomas, solid tumors
Administration Methods Intravenous infusion, often in cycles with rest periods
Combination Therapies Often combined with other drugs like 5-fluorouracil, leucovorin, cisplatin
Dosage Considerations Dosage may be adjusted based on UGT1A1 genotype, exploring reduced doses for certain genetic profiles
Primary Outcomes Studied Tumor response rates, progression-free survival, overall survival, toxicity profiles
Common Side Effects Diarrhea, neutropenia, nausea, vomiting
Unique Aspects Exploration of liposomal formulations, personalized dosing based on genetics

FAQ

  • What is Irinotecan and how does it work? Irinotecan is a chemotherapy drug that fights cancer by interfering with the cancer cells' ability to divide and grow. It works by inhibiting an enzyme called topoisomerase I, which is important for DNA replication in cancer cells.
  • What types of cancer is Irinotecan being studied for? Irinotecan is being studied for various types of cancer, including colorectal cancer, malignant glioma (a type of brain tumor), cervical cancer, sarcomas, and other solid tumors.
  • How is Irinotecan typically administered in clinical trials? In clinical trials, Irinotecan is usually administered intravenously (through a vein). The dosage and frequency can vary depending on the specific trial, but it's often given in cycles, with treatment days followed by rest periods.
  • What are some common side effects of Irinotecan? Common side effects of Irinotecan can include diarrhea, nausea, vomiting, and decreased white blood cell count (neutropenia). The severity of side effects can vary depending on the dosage and individual patient factors.
  • Are there any genetic factors that affect how Irinotecan works? Yes, genetic variations in an enzyme called UGT1A1 can affect how a person's body processes Irinotecan. Some clinical trials are studying how to adjust Irinotecan dosing based on a patient's UGT1A1 genotype to optimize treatment and reduce side effects.

Ongoing Clinical Trials on Irinotecan

  • Study on Colon Cancer Treatment Using Disodium Levofolinate and Drug Combination for Patients with Operable Stage III and High-Risk Stage II Colon Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Spain

  • Study on the Effectiveness of Chemotherapy with Folinic Acid, Fluorouracil, and Irinotecan for Patients with Stage III Colon Cancer After Surgery

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study on Preoperative Treatment with mFOLFIRINOX or Gemcitabine-Paclitaxel for Patients with Borderline Resectable Pancreatic Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium

  • Study of petosemtamab alone or with drug combination for patients with advanced colorectal cancer and other solid tumors

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium France Italy The Netherlands Spain

  • Study Comparing Irinotecan, Fluorouracil, Folinic Acid, and Drug Combination for Patients with Metastatic Pancreatic Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Molecularly Tailored Therapy Versus Standard Care in Patients With Advanced Pancreatic Cancer Using Olaparib, Erlotinib, Crizotinib, Trametinib, Pemigatinib, Selpercatinib, Axitinib, Vismodegib, Pembrolizumab, Larotrectinib, Dabrafenib, Capecitabine, Oxaliplatin, Fluorouracil, Irinotecan, Gemcitabine, Paclitaxel Albumin-Bound, and Calcium Folinate

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Denmark

  • Evaluating the use of capecitabine, oxaliplatin, fluorouracil, folinic acid, and irinotecan to personalize chemotherapy for patients with stage III colorectal cancer

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Sweden

  • Testing continuous versus intermittent treatment with cetuximab, fluorouracil, folinic acid, and irinotecan in patients with newly diagnosed metastatic colorectal cancer

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Germany

  • Study comparing cetuximab with chemotherapy versus bevacizumab with chemotherapy in patients with advanced colorectal cancer who have wild-type RAS and right-sided tumors

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Spain

  • Study of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Denmark France Germany Italy +4

Glossary

  • Irinotecan: A chemotherapy drug that inhibits topoisomerase I, an enzyme involved in DNA replication. It's used to treat various types of cancer, especially colorectal cancer.
  • CPT-11: Another name for Irinotecan, often used in clinical and research settings.
  • Camptosar: The brand name for Irinotecan.
  • Topoisomerase I: An enzyme that helps in the process of DNA replication. Irinotecan works by inhibiting this enzyme in cancer cells.
  • FOLFIRI: A chemotherapy regimen that combines Irinotecan with other drugs, typically including 5-fluorouracil and leucovorin.
  • UGT1A1: An enzyme involved in metabolizing Irinotecan. Genetic variations in UGT1A1 can affect how a person responds to Irinotecan treatment.
  • Neutropenia: A decrease in white blood cells called neutrophils, which can be a side effect of chemotherapy and increase the risk of infections.
  • Dose-limiting toxicity (DLT): Side effects that are severe enough to prevent increasing the dose of a drug in a clinical trial.
  • Maximum tolerated dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.

References

  1. https://clinicaltrials.gov/study/NCT01925274
  2. https://clinicaltrials.gov/study/NCT00002902
  3. https://clinicaltrials.gov/study/NCT02296203
  4. https://clinicaltrials.gov/study/NCT01654081
  5. https://clinicaltrials.gov/study/NCT01308632
  6. https://clinicaltrials.gov/study/NCT00336856
  7. https://clinicaltrials.gov/study/NCT02935764
  8. https://clinicaltrials.gov/study/NCT01163396
  9. https://clinicaltrials.gov/study/NCT00875771